Advertisement

Cost Effectiveness of Influenza Vaccine for U.S. Children

Live Attenuated and Inactivated Influenza Vaccine

      Introduction

      Prior studies showed that live attenuated influenza vaccine (LAIV) is more effective than inactivated influenza vaccine (IIV) in children aged 2–8 years, supporting the Centers for Disease Control and Prevention (CDC) recommendations in 2014 for preferential LAIV use in this age group. However, 2014–2015 U.S. effectiveness data indicated relatively poor effectiveness of both vaccines, leading CDC in 2015 to no longer prefer LAIV.

      Methods

      An age-structured model of influenza transmission and vaccination was developed, which incorporated both direct and indirect protection induced by vaccination. Based on this model, the cost effectiveness of influenza vaccination strategies in children aged 2–8 years in the U.S. was estimated. The base case assumed a mixed vaccination strategy where 33.3% and 66.7% of vaccinated children aged 2–8 years receive LAIV and IIV, respectively. Analyses were performed in 2014–2015.

      Results

      Using published meta-analysis vaccine effectiveness data (83% LAIV and 64% IIV), exclusive LAIV use would be a cost-effective strategy when vaccinating children aged 2–8 years, whereas IIV would not be preferred. However, when 2014–2015 U.S. effectiveness data (0% LAIV and 15% IIV) were used, IIV was likely to be preferred.

      Conclusions

      The cost effectiveness of influenza vaccination in children aged 2–8 years is highly dependent on vaccine effectiveness; the vaccine type with higher effectiveness is preferred. In general, exclusive IIV use is preferred over LAIV use, as long as vaccine effectiveness is higher for IIV than for LAIV.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Centers for Disease Control and Prevention (CDC)
        Estimates of deaths associated with seasonal influenza—United States, 1976-2007.
        MMWR Morb Mortal Wkly Rep. 2010; 59: 1057-1062
        • Clements K.M.
        • Meier G.
        • McGarry L.J.
        • Pruttivarasin N.
        • Misurski D.A.
        Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
        Hum Vaccin Immunother. 2014; 10: 1171-1180https://doi.org/10.4161/hv.28221
        • Luce B.R.
        • Nichol K.L.
        • Belshe R.B.
        • et al.
        Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
        Vaccine. 2008; 26: 2841-2848https://doi.org/10.1016/j.vaccine.2008.03.046
        • Fiore A.E.
        • Uyeki T.M.
        • Broder K.
        • et al.
        Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
        MMWR Recomm Rep. 2010; 59: 1-62
        • Ambrose C.S.
        • Levin M.J.
        • Belshe R.B.
        The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.
        Influenza Other Respir Viruses. 2011; 5: 67-75https://doi.org/10.1111/j.1750-2659.2010.00183.x
      1. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) reaffirms recommendation for annual influenza vaccination. www.cdc.gov/media/releases/2015/s0226-acip.html. Published 2015. Accessed April 14, 2015.

        • Prosser L.A.
        • Bridges C.B.
        • Uyeki T.M.
        • et al.
        Health benefits, risks, and cost-effectiveness of influenza vaccination of children.
        Emerg Infect Dis. 2006; 12: 1548-1558https://doi.org/10.3201/eid1210.051015
        • Thommes E.W.
        • Ismaila A.
        • Chit A.
        • Meier G.
        • Bauch C.T.
        Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
        BMC Infect Dis. 2015; 15: 465https://doi.org/10.1186/s12879-015-1193-4
        • Damm O.
        • Eichner M.
        • Rose M.A.
        • et al.
        Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.
        Eur J Health Econ. 2015; 16: 471-488https://doi.org/10.1007/s10198-014-0586-4
        • Shim E.
        • Galvani A.P.
        Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.
        Vaccine. 2009; 27: 4025-4030https://doi.org/10.1016/j.vaccine.2009.04.030
        • Atkins K.E.
        • Shim E.
        • Carroll S.
        • Quilici S.
        • Galvani A.P.
        The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
        Vaccine. 2012; 30: 6766-6776https://doi.org/10.1016/j.vaccine.2012.09.025
        • Jit M.
        • Brisson M.
        • Laprise J.F.
        • Choi Y.H.
        Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
        BMJ. 2015; 350: g7584https://doi.org/10.1136/bmj.g7584
        • Laprise J.F.
        • Drolet M.
        • Boily M.C.
        • et al.
        Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
        Vaccine. 2014; 32: 5845-5853https://doi.org/10.1016/j.vaccine.2014.07.099
        • Galvani A.P.
        • Reluga T.C.
        • Chapman G.B.
        Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum.
        Proc Natl Acad Sci U S A. 2007; 104: 5692-5697https://doi.org/10.1073/pnas.0606774104
        • Longini Jr., I.M.
        • Halloran M.E.
        • Nizam A.
        • Yang Y.
        Containing pandemic influenza with antiviral agents.
        Am J Epidemiol. 2004; 159: 623-633https://doi.org/10.1093/aje/kwh092
        • Hsu S.B.
        • Hsieh Y.H.
        On the role of asymptomatic infection in transmission dynamics of infectious diseases.
        Bull Math Biol. 2008; 70: 134-155https://doi.org/10.1007/s11538-007-9245-6
        • Mossong J.
        • Hens N.
        • Jit M.
        • et al.
        Social contacts and mixing patterns relevant to the spread of infectious diseases.
        PLoS Med. 2008; 5: e74https://doi.org/10.1371/journal.pmed.0050074
        • Centers for Disease Control and Prevention (CDC)
        Estimated influenza illnesses and hospitalizations averted by influenza vaccination—United States, 2012-13 influenza season.
        MMWR Morb Mortal Wkly Rep. 2013; 62: 997-1000
        • Gail M.H.
        • Benichou J.
        Encyclopedia of Epidemiologic Methods.
        Wiley, New York2000
        • Shim E.
        • Galvani A.P.
        Distinguishing vaccine efficacy and effectiveness.
        Vaccine. 2012; 30: 6700-6705https://doi.org/10.1016/j.vaccine.2012.08.045
      2. Centers for Disease Control and Prevention (CDC). FluVaxView. State, Regional, and National Vaccination Coverage. Atlanta, GA: CDC.
        • Osterholm M.T.
        • Kelley N.S.
        • Sommer A.
        • Belongia E.A.
        Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.
        Lancet Infect Dis. 2012; 12: 36-44https://doi.org/10.1016/S1473-3099(11)70295-X
        • Weycker D.
        • Edelsberg J.
        • Halloran M.E.
        • et al.
        Population-wide benefits of routine vaccination of children against influenza.
        Vaccine. 2005; 23: 1284-1293https://doi.org/10.1016/j.vaccine.2004.08.044
        • Tarride J.E.
        • Burke N.
        • Von Keyserlingk C.
        • O’Reilly D.
        • Xie F.
        • Goeree R.
        Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents.
        Clinicoecon Outcomes Res. 2012; 4: 287-298https://doi.org/10.2147/CEOR.S33444
      3. Centers for Disease Control and Prevention (CDC). CDC vaccine price list. www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Published 2015. Accessed May 2015.

        • Kahn K.E.
        • Santibanez T.A.
        • Zhai Y.
        • Singleton J.A.
        Influenza vaccination type, live, attenuated influenza vaccine (LAIV) versus inactivated influenza vaccine (IIV), received by children, United States, 2011-12 through 2013-14 influenza seasons.
        Vaccine. 2015; 33: 5196-5203https://doi.org/10.1016/j.vaccine.2015.07.064
        • WHO
        Report of the Commission on Macroeconomics and Health.
        WHO, Geneva2002
        • Grohskopf L.A.
        • Olsen S.J.
        • Sokolow L.Z.
        • et al.
        Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014-15 influenza season.
        MMWR Morb Mortal Wkly Rep. 2014; 63: 691-697
        • Andersohn F.
        • Bornemann R.
        • Damm O.
        • Martin F.
        • Mittendorf T.
        • Theidel U.
        Vaccination of children with a live-attenuated, intranasal influenza vaccine—analysis and evaluation through a Health Technology Assessment.
        GMS Health Technol Assess. 2014; 10 (http://dx.doi.org/10.3205/hta000119): Doc30
        • Jefferson T.
        • Rivetti A.
        • Di Pietrantonj C.
        • Demicheli V.
        • Ferroni E.
        Vaccines for preventing influenza in healthy children.
        Cochrane Database Syst Rev. 2012; 8: CD004879https://doi.org/10.1002/14651858.cd004879.pub4
      4. Flannery B, Clippard JR. Updated interim influenza vaccine effectiveness estimates by age group and vaccine type for the 2014-15 season: updates from the U.S. Influenza Vaccine Effectiveness (Flu VE) Network. www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-02/flu-01-Flannery.pdf.